Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19886817 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL3171617 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL29541499 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4143916 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL267542 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4148516 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL1627440 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4140372 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4149480 | 1.00 | USP2 (0.63) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL17744972 | 0.92 | TSHR (0.62) | USP2TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3406614-B1 | OPIOID RECEPTOR ANTAGONIST CONJUGATE AND USE THEREOF | SHANGHAI HANMAI BIO PHARMA CO LTD (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-11311533-B2 | Opioid receptor antagonist conjugate and use thereof | Shanghai Hanmai Bio-Pharma Co., Ltd. (CN) | 2022-04-26 | — | — | US | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-1273917-B1 | Acridinium ester labels having hydrophilic modifiers | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8710097-B2 | Flavonoid dimers and methods of making and using such | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2014-04-29 | — | — | US | disclosed |
| US-20090197943-A1 | Flavonoid Dimers and Methods of Making and Using Such | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2009-08-06 | — | — | US | disclosed |
| EP-2029568-A1 | FLAVONOID DIMERS AND METHODS OF MAKING AND USING SUCH | The Hong Kong Polytechnic University (CN) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135592-A1 | FLAVONOID DIMERS AND METHODS OF MAKING AND USING SUCH | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2007-11-29 | — | — | WO | disclosed |
| US-6664043-B2 | Detectable chemiluminescent acridinium ester label, comprising an acridinium ester with a hydrophilic modifier | BAYER CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-20030045716-A1 | Acridinium ester labels having hydrophilic modifiers | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1273917-A2 | Acridinium ester labels having hydrophilic modifiers | Bayer Corporation (US) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045716-A1 | Acridinium ester labels having hydrophilic modifiers | SRM, SMS, ACR | USP2 2452/4885TSHR 664/4885ALDH1A1 865/4885 |
| US-11311533-B2 | Opioid receptor antagonist conjugate and use thereof | OPRL1, OPRM1, OGFR | USP2 2647/4885TSHR 347/4885ALDH1A1 756/4885 |
| US-20090197943-A1 | Flavonoid Dimers and Methods of Making and Using Such | ABCB1, ABCC1, SLC47A2 | USP2 3690/4885TSHR 4591/4885ALDH1A1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.